Effects of amiodarone therapy on thyroid function

作者: Janna Cohen-Lehman , Peter Dahl , Sara Danzi , Irwin Klein

DOI: 10.1038/NRENDO.2009.225

关键词:

摘要: Amiodarone is a benzofuran derivative approved for the treatment of cardiac arrhythmias. Traditionally classified as class III antiarrhythmic agent, amiodarone possesses electrophysiologic properties all four Vaughan-Williams classes. This drug, however, has high iodine content, and this feature plus intrinsic effects on body make especially toxic to thyroid gland. Treatment can result in range from mild derangements function overt hypothyroidism or thyrotoxicosis. The diagnosis amiodarone-induced usually straightforward, whereas that thyrotoxicosis ability distinguish between type 1 2 forms disease are much more challenging. Dronedarone was 2009 patients with atrial fibrillation. As amiodarone, dronedarone similar properties. In contrast structurally devoid notably shorter half-life. studies reported before FDA approval, proved be associated significantly fewer adverse than making it attractive choice fibrillation flutter, who at risk developing dysfunction.

参考文章(63)
G Neal Kay, Juan L Tamargo, Jonathan L Halperin, Anne B Curtis, S Bertil Olsson, Valentín Fuster, Samuel Wann, David S Cannom, Jean-Yves Le Heuzey, Eric N Prystowsky, Lars E Rydén, Harry J Crijns, Kenneth A Ellenbogen, James E Lowe, Guidelines for the management of patients with atrial fibrillation. Executive summary Revista Espanola De Cardiologia. ,vol. 59, pp. 1329- ,(2006)
Robert O. Bonow, Peter Libby, Eugene Braunwald, Douglas P. Zipes, Douglas L. Mann, Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine ,(2011)
Fausto Bogazzi, Luigi Bartalena, Maurizio Gasperi, Lewis E. Braverman, Enio Martino, The various effects of amiodarone on thyroid function. Thyroid. ,vol. 11, pp. 511- 519 ,(2001) , 10.1089/105072501300176471
Aldo Pinchera, Lewis E. Braverman, Francesco Lippi, Lidio Baschieri, Fabrizio Aghini-Lombardi, Enio Martino, Marjorie Safran, Twenty-Four Hour Radioactive Iodine Uptake in 35 Patients with Amiodarone Associated Thyrotoxicosis The Journal of Nuclear Medicine. ,vol. 26, pp. 1402- 1407 ,(1985)
Shehzad Basaria, David S. Cooper, Amiodarone and the thyroid The American Journal of Medicine. ,vol. 118, pp. 706- 714 ,(2005) , 10.1016/J.AMJMED.2004.11.028
Stefan H. Hohnloser, New pharmacological options for patients with atrial fibrillation: the ATHENA trial. Revista Espanola De Cardiologia. ,vol. 62, pp. 479- 481 ,(2009) , 10.1016/S1885-5857(09)71829-8
S. E. M. Eaton, H. A. Euinton, C. M. Newman, A. P. Weetman, W. M. Bennet, Clinical experience of amiodarone‐induced thyrotoxicosis over a 3‐year period: role of colour‐flow Doppler sonography* Clinical Endocrinology. ,vol. 56, pp. 33- 38 ,(2002) , 10.1046/J.0300-0664.2001.01457.X
Fausto Bogazzi, Luca Tomisti, Giuseppe Rossi, Enrica Dell'Unto, Pasquale Pepe, Luigi Bartalena, Enio Martino, Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study The Journal of Clinical Endocrinology and Metabolism. ,vol. 94, pp. 3757- 3762 ,(2009) , 10.1210/JC.2009-0940
S. Tedelind, F. Larsson, C. Johanson, H. C. van Beeren, W. M. Wiersinga, E. Nyström, M. Nilsson, Amiodarone inhibits thyroidal iodide transport in vitro by a cyclic adenosine 5'-monophosphate- and iodine-independent mechanism Endocrinology. ,vol. 147, pp. 2936- 2943 ,(2006) , 10.1210/EN.2005-1246
F. Osman, J.A. Franklyn, M.C. Sheppard, M.D. Gammage, Successful Treatment of Amiodarone-Induced Thyrotoxicosis Circulation. ,vol. 105, pp. 1275- 1277 ,(2002) , 10.1016/S1062-1458(02)00767-5